Grammidin with neo anesthetic is a combined drug for the treatment of infectious and inflammatory diseases of the throat and oral cavity. The drug contains the antimicrobial agent gramicidin C, a local anesthetic (pain reliever) - oxybuprocaine and an antiseptic - cetylpyridinium chloride.
The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which disrupts its stability and causes cell death. Gramicidin C has a pronounced antimicrobial effect against pathogens of infectious diseases of the oral cavity and pharynx.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
$180.85$350.99
Syndicate customized growth strategies prospective human capital leverage other's optimal e-markets without transparent catalysts for change. Credibly coordinate highly efficient methods of empowerment cross unit solutions.
"Valenta Pharm" is a Russian pharmaceutical company founded in 1997 and engaged in the development, production and market launch of high—quality prescription and over-the-counter drugs.
Over the past 27 years, the company "Valenta Pharm" has successfully developed and marketed a number of drugs in such therapeutic areas as immunology, virology, neuropsychiatry, gastroenterology, etc.
At the moment, the company produces about 100 million dosage forms of finished medicines per year in most socially significant pharmacotherapeutic groups.